Medical Condition News

RSS

Pharming Group NV's pre-BLA meeting with the FDA for Rhucin

Biotech company Pharming Group NV today confirmed its interactions in a pre-BLA meeting with the US Food and Drug Administration (FDA) on a proposed marketing application (BLA or Biologics License Application) to obtain marketing approval for Rhucin for the treatment of acute attacks of HAE (Hereditary Angioedema).

9 Dec 2009

Utility of CEH-EUS uses sonographic contrast agent to diagnose pancreatic tumors

Endoscopic ultrasonography (EUS) is a highly sensitive diagnostic method for the detection of small pancreatic carcinomas. Recently, there have been some reports describing the utility of contrast-enhanced harmonic EUS (CEH-EUS) which uses sonographic contrast agent for differentiation of a pancreatic mass.

9 Dec 2009

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

The second phase of a clinical trial testing a new stem-cell-based therapy on injured heart muscle has been launched by researchers at The University of Texas Medical School at Houston. It is the only study site in the Texas Medical Center.

9 Dec 2009

Successful reduction in the levels of aggregated Abeta with GSMs

EnVivo Pharmaceuticals today reported the successful reduction in the levels of aggregated Abeta or Beta-Amyloid in an aged transgenic model (Tg2576) of Alzheimer's disease with its lead gamma-secretase modulator (GSM) EVP-0962. The aggregated Abeta, containing predominately oligomeric and larger Abeta fibrillar species, is considered to be the toxic entity in Alzheimer's disease.

9 Dec 2009

Colon Cancer Alliance's statement regarding a new report on drop in colorectal cancer

A recent study by the Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) highlighting that the death rate from colorectal cancer over the last decade dropped nearly 20 percent and that by 2020 could be cut in half is welcomed news.

9 Dec 2009

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Lung cancer is the leading cause of cancer mortality worldwide and lung adenocarcinoma is the most common type. Many cases of lung adenocarcinoma are attributed to a mutation in a gene for the epidermal growth factor receptor (EGFR).

9 Dec 2009

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Celgene International Sàrl announced that investigational data evaluating combination therapy with REVLIMID (lenalidomide) and rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) were presented during the 51st American Society of Hematology’s annual meeting in New Orleans, LA.

9 Dec 2009

Psychological trauma leaves a trail of damage in a child's brain, reveal scientists

Psychological trauma leaves a trail of damage in a child's brain, say scientists at the Stanford University School of Medicine and Lucile Packard Children's Hospital. Their new study gives the first direct evidence that children with symptoms of post-traumatic stress suffer poor function of the hippocampus, a brain structure that stores and retrieves memories. The research helps explain why traumatized children behave as they do and could improve treatments for these kids.

9 Dec 2009

NeuroPace announces clinical trial results demonstrating the RNS System

NeuroPace, Inc. today announced that results from its pivotal trial demonstrated the RNS- System, a novel investigational device that utilizes responsive brain neurostimulation, significantly reduced the frequency of seizures among people who have a common form of epilepsy that is difficult to treat with medication.

9 Dec 2009

TMZ and small molecule combination appears to lower tumor resistance

University of Florida researchers have found a way to use just a fraction of the normal dosage of a highly toxic, debilitating chemotherapy drug to achieve even better results against colon cancer cells.

9 Dec 2009

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil (plerixafor injection) in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

9 Dec 2009

Kennedy Krieger Institute opens new center for individuals with muscle disorders

Kennedy Krieger Institute announced today the opening of the new Center for Genetic Muscle Disorders that will improve and expand services to individuals with muscle disorders such as muscular dystrophy and congenital myopathy in the Baltimore/Washington region and across the nation. The Center provides expert clinical care to children and adults with these disorders, and offers leading research programs both in the clinical and laboratory setting.

9 Dec 2009

Phase II clinical trial results of Doxorubicin Transdrug announced

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces positive survival data in its phase II clinical trial with doxorubicin Transdrug® in patients with advanced hepatocellular carcinoma (primary liver cancer).

9 Dec 2009

Antithrombotic medication may increase risk of bleeding in dialysis patients undergoing PCI procedure

Approximately 20 percent of dialysis patients undergoing a percutaneous coronary intervention (PCI; procedure such as angioplasty) are given an antithrombotic medication they should not receive, which may increase their risk for in-hospital bleeding, according to a study in the December 9 issue of JAMA.

9 Dec 2009

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

GlaxoSmithKline announced today updated long-term survival data from two Phase II studies of BEXXAR® (tositumomab and iodine I-131 tositumomab) used in either patients with previously untreated cancer of the immune system (follicular lymphoma) or in patients with cancer of the lymphocytes (non-Hodgkin's lymphoma, NHL) that no longer responded to rituximab.

9 Dec 2009

Spine system: A new technique to treat lower back pain

Using a branch of science that crosses disciplines to study complex problems, a Michigan State University researcher is introducing a new way to understand and treat lower back pain, a condition affecting more than 40 million Americans and costing billions of dollars each year.

9 Dec 2009

Tips for people with eating disorder

Many people equate the holidays with food - big meals equals big times. Americans, especially, attach a lot of social and personal value to what, and how, we eat, often through family rituals or attitudes. For many, family gatherings are positive events, but for the 9 million men, women or young people who have an eating disorder, the holidays, without proper planning, can feel like nightmares.

9 Dec 2009

Biomarkers can be important in identifying PTSD symptoms, says researchers

Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) frequently experience high rates of PTSD along with symptoms of depression and pain. However, little is known about why these symptoms occur together or the most effective treatments that can be used to alleviate them. One approach that may yield new insights is to search for biomarkers -- indicators of a biological state that can be easily and reliably measured in people with an illness -- to see if their presence or absence can predict symptoms that an individual will experience and identify optimal treatment strategies.

9 Dec 2009

Most antidepressant medications raise serotonin levels and miss key target of clinical depression

A key brain protein called monoamine oxidase A (MAO-A) - is highly elevated during clinical depression yet is unaffected by treatment with commonly used antidepressants, according to an important study published today in the Archives of General Psychiatry. The study has important implications for our understanding of why antidepressants don't always work.

9 Dec 2009

Progenitor-cell therapy can reduce risk of another heart attack

Cells from heart attack survivors' own bone marrow reduced the risk of death or another heart attack when they were infused into the affected artery after successful stent placement, according to research reported in the American Heart Association journal Circulation: Heart Failure.

9 Dec 2009

Medical Condition News

Pharming Group NV's pre-BLA meeting with the FDA for Rhucin

Utility of CEH-EUS uses sonographic contrast agent to diagnose pancreatic tumors

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

Successful reduction in the levels of aggregated Abeta with GSMs

Colon Cancer Alliance's statement regarding a new report on drop in colorectal cancer

Mouse model may help identify unknown mutations that make lung cancer cells resistant to therapy

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Psychological trauma leaves a trail of damage in a child's brain, reveal scientists

NeuroPace announces clinical trial results demonstrating the RNS System

TMZ and small molecule combination appears to lower tumor resistance

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Kennedy Krieger Institute opens new center for individuals with muscle disorders

Phase II clinical trial results of Doxorubicin Transdrug announced

Antithrombotic medication may increase risk of bleeding in dialysis patients undergoing PCI procedure

GSK updates long-term survival data of BEXXAR Therapeutic Regimen for Non-Hodgkin's lymphoma

Spine system: A new technique to treat lower back pain

Tips for people with eating disorder

Biomarkers can be important in identifying PTSD symptoms, says researchers

Most antidepressant medications raise serotonin levels and miss key target of clinical depression

Progenitor-cell therapy can reduce risk of another heart attack

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News